These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 30979742)

  • 1. Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
    Coats S; Williams M; Kebble B; Dixit R; Tseng L; Yao NS; Tice DA; Soria JC
    Clin Cancer Res; 2019 Sep; 25(18):5441-5448. PubMed ID: 30979742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
    Ma H; Sawas A
    Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
    Hedrich WD; Fandy TE; Ashour HM; Wang H; Hassan HE
    Clin Pharmacokinet; 2018 Jun; 57(6):687-703. PubMed ID: 29188435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
    Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
    J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cancer with antibody-drug conjugates: Promises and challenges.
    Dean AQ; Luo S; Twomey JD; Zhang B
    MAbs; 2021; 13(1):1951427. PubMed ID: 34291723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances of antibody drug conjugates for clinical applications.
    Zhao P; Zhang Y; Li W; Jeanty C; Xiang G; Dong Y
    Acta Pharm Sin B; 2020 Sep; 10(9):1589-1600. PubMed ID: 33088681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.
    Martin C; Kizlik-Masson C; Pèlegrin A; Watier H; Viaud-Massuard MC; Joubert N
    MAbs; 2018; 10(2):210-221. PubMed ID: 29239690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
    Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
    Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates in solid tumors: a look into novel targets.
    Criscitiello C; Morganti S; Curigliano G
    J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calicheamicin Antibody-Drug Conjugates with Improved Properties.
    Vollmar BS; Frantz C; Schutten MM; Zhong F; Del Rosario G; Go MAT; Yu SF; Leipold DD; Kamath AV; Ng C; Xu K; Dela Cruz-Chuh J; Kozak KR; Chen J; Xu Z; Wai J; Adhikari P; Erickson HK; Dragovich PS; Polson AG; Pillow TH
    Mol Cancer Ther; 2021 Jun; 20(6):1112-1120. PubMed ID: 33722856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antibody-drug conjugates: a new therapeutic class?].
    Chofflon I; Dietrich PY; Thang NN
    Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
    Pondé N; Aftimos P; Piccart M
    Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugate technology development for hematologic disorders.
    Bander NH; Czuczman MS; Younes A
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
    Chu Y; Zhou X; Wang X
    J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linked-in: design and efficacy of antibody drug conjugates in oncology.
    Feld J; Barta SK; Schinke C; Braunschweig I; Zhou Y; Verma AK
    Oncotarget; 2013 Mar; 4(3):397-412. PubMed ID: 23651630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.